Discover
TOVX
Theriva Biologics, Inc.
0.23
300 x 0.23
300 x 0.24
bid
ask
-
0.01
3.51%
300 @ 07:55 PM
0.24 +0.01 (2.78%)
| Ytd | 11.19% | |
| 1y | -43.05% |
0.23
day range
0.24
0.18
52 week range
0.84
| Open | 0.24 | Prev Close | 0.24 | Low | 0.23 | High | 0.24 | Mkt Cap | 10.72M |
| Vol | 198.59K | Avg Vol | 1.20M | EPS | 1.44 | P/E | 0.16 | Forward P/E | -0.07 |
| Beta | 1.34 | Short Ratio | 0.03 | Inst. Own | 21.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.23 | 200-d Avg | 0.24 | 1yr Est | 90.50 |
| Income Statement | |||
| Operating Expenses | 3.30M | ||
| Research and Development Expense | 1.27M | ||
| Selling, General and Administrative Expense | 2.03M | ||
| Operating Income | -3.29M | ||
| Net Income | -3.22M | ||
| Net Income Common Stock | -3.22M | ||
| Net Income Common Stock (USD) | -3.22M | ||
| Consolidated Income | -3.22M | ||
| Earnings per Basic Share | -0.07 | ||
| Earnings per Basic Share (USD) | -0.07 | ||
| Earnings per Diluted Share | -0.07 | ||
| Earning Before Interest & Taxes (EBIT) | -3.22M | ||
| Earning Before Interest & Taxes (USD) | -3.22M | ||
| Weighted Average Shares | 45.89M | ||
| Weighted Average Shares Diluted | 45.89M | ||
| Balance Sheet | |||
| Cash and Equivalents | 11.38M | ||
| Cash and Equivalents (USD) | 11.38M | ||
| Current Assets | 13.67M | ||
| Property, Plant & Equipment Net | 2.00M | ||
| Total Assets | 34.86M | ||
| Debt Current | 559.00K | ||
| Total Debt | 3.55M | ||
| Current Liabilities | 12.11M | ||
| Debt Non-Current | 2.99M | ||
| Total Liabilities | 22.67M | ||
| Accumulated Retained Earnings (Deficit) | -363.97M | ||
| Accumulated Other Comprehensive Income | 247.00K | ||
| Shareholders Equity | 12.19M | ||
| Shareholders Equity (USD) | 12.19M | ||
| Assets Non-Current | 21.19M | ||
| Total Debt (USD) | 3.55M | ||
| Liabilities Non-Current | 10.56M | ||
| Trade and Non-Trade Payables | 984.00K | ||
| Tax Assets | 1.68M | ||
| Tax Liabilities | 1.61M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 135.00K | ||
| Net Cash Flow from Financing | -14.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.09M | ||
| Capital Expenditure | -3.00K | ||
| Issuance (Repayment) of Debt Securities | -11.00K | ||
| Net Cash Flow from Investing | -3.00K | ||
| Net Cash Flow from Operations | -3.08M | ||
| Effect of Exchange Rate Changes on Cash | 7.00K | ||
| Share Based Compensation | 135.00K | ||